Idiopathic Pulmonary Fibrosis: How to Recognize and When to Refer

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

Novel Nasally-administered Monoclonal Antibody Reduces Inflammation in COVID-19

Tezepelumab Effective in Severe Asthma Cohorts Stratified by Age at Onset, Inflammatory Phenotype, and Allergen Sensitization

For Persons with Asthma Infected with COVID-19, Systemic Corticosteroid Prescribing is Up

FDA Accepts Pfizer BLA for Maternal RSV Vaccine for Priority Review

Use of Multiple Specimen Types in RSV Testing May Improve Detection Rates, Suggests New Review and Meta-analysis

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

Novel Nasally-administered Monoclonal Antibody Reduces Inflammation in COVID-19

Tezepelumab Effective in Severe Asthma Cohorts Stratified by Age at Onset, Inflammatory Phenotype, and Allergen Sensitization

For Persons with Asthma Infected with COVID-19, Systemic Corticosteroid Prescribing is Up

FDA Accepts Pfizer BLA for Maternal RSV Vaccine for Priority Review

Use of Multiple Specimen Types in RSV Testing May Improve Detection Rates, Suggests New Review and Meta-analysis

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

Novel Nasally-administered Monoclonal Antibody Reduces Inflammation in COVID-19

Tezepelumab Effective in Severe Asthma Cohorts Stratified by Age at Onset, Inflammatory Phenotype, and Allergen Sensitization

For Persons with Asthma Infected with COVID-19, Systemic Corticosteroid Prescribing is Up

FDA Accepts Pfizer BLA for Maternal RSV Vaccine for Priority Review

Use of Multiple Specimen Types in RSV Testing May Improve Detection Rates, Suggests New Review and Meta-analysis

Related Content

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

Adding paired serology and sputum to nasal swab/nasopharyngeal swabs RT-PCR increased RSV detection by 50% to 66% on average, respectively.

Novel Nasally-administered Monoclonal Antibody Reduces Inflammation in COVID-19

Podcast

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Tezepelumab Effective in Severe Asthma Cohorts Stratified by Age at Onset, Inflammatory Phenotype, and Allergen Sensitization

Delivered intranasally, the fully human anti-CD3 mAb Foralumab modulated T-cell inflammation in COVID-19 and may have wider application, say study authors.

For Persons with Asthma Infected with COVID-19, Systemic Corticosteroid Prescribing is Up

AAAAI 2023. The TSLP inhibitor was superior to placebo in 2 post hoc analyses of the PATHWAY and NAVIGATOR clinical trials.

FDA Accepts Pfizer BLA for Maternal RSV Vaccine for Priority Review

AAAAI 2023. Pandemic prescribing rates for systemic corticosteroids increased from Alpha to Delta to Omicron waves of COVID-19 but hospitalizations have dropped, study finds.